Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Apr
17
UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance
Jan
18
Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis
Jan
06
UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review
Dec
23
UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab
Nov
22
UCB Submits Response to FDA Complete Response Letter for Bimekizumab
Nov
14
UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients
Sep
26
UCB U.S. Headquarters in Atlanta Awarded Prestigious LEED Gold WELL Platinum Certifications
Sep
22
UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting
Aug
17
UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters
